Therapeutic Drug Monitoring ELISA Assay

Rituximab mAb-based ELISA Assay

$1,415.00

The Rituximab mAb-based ELISA Assay is developed for specific measurement of Rituximab in serum and plasma.  The kit is a solid phase enzyme-linked immunosorbent assay (ELISA) is based on rituximab-specific 9F9 monoclonal antibody (mAb).  The Rituximab (Rituxan®, Mabthera®) ELISA (mAb-based) Assay Kit  is for research use only and is not intended for diagnostic or therapeutic procedures.

SKU: IG-AB106 Categories: , ,

Rituximab mAb-based ELISA Assay

The Rituximab mAb-based ELISA Assay is For Research Use Only

Size: 1 x 96 wells
Sensitivity: 2 ng/mL
Dynamic Range: 6 – 200 ng/mL
Incubation Time: 2 hours
Sample Type: Serum, Plasma
Sample Size: 10 µL
Alternative Names: Rituxan, Mabthera

Controls Included

Assay Background

The drug Rituximab (trade name Rituxan® and Mabthera®) is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is a glycosylated IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences (Fab domain) and human constant region sequences (Fc domain). Rituximab is composed of 1,328 amino acids and has an approximate molecular weight of 144 kD. Rituximab has a high binding affinity for the CD20 antigen.

The specificity of this test system is achieved by using a monoclonal antibody (clon 9D5b) for the coating of the microtiter plate. This antibody is specific for Rituximab only (regardless whether Rituxan ® and Mabthera ®) and does not cross react with other CD20 catchers.

STORAGE AND STABILITY OF THE KIT
The kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sun light. The microtiter strips are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2–8°C. The usual precautions for venipuncture should be observed. It is important to preserve the chemical integrity of a blood specimen from the moment it is collected until it is assayed. Do not use grossly hemolytic, icteric or grossly lipemic specimens. Samples appearing turbid should be centrifuged before testing to remove any particulate material.

Related Products

Anti-Rituximab (Rituxan) ELISA Kit
Rituximab (Rituxan) ELISA Assay
Ustekinumab mAb-based ELISA

Additional Information

Assay Principle

This Eagle Biosciences Rituximab ELISA is based on Rituximab-specific mouse monoclonal antibody (catcher Ab, ImmunoGuide clone IG-9D5b). Diluted standards and samples are incubated in the microtiter plate coated with IG-9D5b mAb. After incubation, the wells are washed. A horseradish peroxidase (HRP)-conjugated anti-human IgG monoclonal antibody is added and binds to the Fc part of Rituximab. Following incubation, wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. The colour developed is proportional to the amount of Rituximab in the sample or standard. Results of samples can be determined by using the standard curve. Binding of Rituximab to the solid phase, pre-coated with 9D5b, is inhibited by recombinant human CD20 protein. Therefore, the ImmunoGuide Rituximab ELISA (mAb-Based) measures the free form of Rituximab.

Assay Procedure

  1. Pipette 100 µL of Assay Buffer into each of the wells to be used.
  2. Pipette 75 µL of each 1:10 Diluted Standard, and 1:2000 Diluted Samples into the respective wells of the microtiter plate.
  3. Cover the plate with adhesive seal. Shake plate carefully. Incubate 60 min at room temperature (RT, 20-25°C).
  4. Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate 3 X 300 μL of Diluted Wash Buffer per well. Remove excess solution by tapping the inverted plate on a paper towel.
  5. Pipette 100 μL of Enzyme Conjugate (HRP-anti human IgG mAb) into each well.
  6. Cover plate with adhesive seal. Shake plate carefully. Incubate 30 min at RT.
  7. Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate 3 X 300 μL of Diluted Wash Buffer per well. Remove excess solution by tapping the inverted plate on a paper towel.
  8. Pipette 100 µL of Ready-to-Use TMB Substrate Solution into each well.
  9. Incubate 10 min at RT. Avoid exposure to direct sunlight.
  10. Stop the substrate reaction by adding 100 µL of Stop Solution into each well. Briefly mix contents by gently shaking the plate. Color changes from blue to yellow.
  11. Measure optical density (OD) with a photometer at 450 nm (Reference at OD620 nm is optional) within 15 min after pipetting the Stop Solution.

Typical Standard Curve

Documents

Product Manual

 

Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Publications

Citations

  • Adisen E, et al,  Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study, Journal of Dermatology (2010)
  • Kato S, et al, Elevated Serum IgE Prior to Acute Severe Infusion Reaction During Infliximab Maintenance Therapy in a Crohn’s Disease Patient, Crohn’s & Colitis Foundation of America (2011)
  • Malickova K, et al, Formation of antiphospholipid antibodies and antibodies to infliximab in anti-TNF-alpha antibody-treated patients with inflammatory bowel diseases, Czech Republic (2011)
  • Malickova K, et al, Relationship between serum trough infliximab levels, serum antibodies to infliximab, serum albumin levels and clinical response to infliximab treatment in patients with inflammatory bowel diseases, Czech Republic (2011)
  • Molnar T, et al, Importance of trough levels and antibody titers on the efficacy and safety of Infliximab therapy in inflammatory bowel disease, Hungary (2012)
  • Bodini G, et al, Clinical relevance of Adalimumab serum concentration and Anti-Adalimumab antibodies in patients with Chrohn’s disease during long-term follow up, Italy (2012)
  • Bortlik M, et al, Infliximab trough levels may predict sustained response to infliximab in patients with Crohn’s disease, Journal of Crohn’s and Colitis (2012)
  • Takahashi H, et al, Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis, Journal of Dermatology (2012)
  • Seok Lee Y, et al, Efficacy of Early Infliximab Treatment for Pediatric Crohn’s Disease: A Three-year Follow-up, Pediatric Gastroenterology, Hepatology & Nutrition (2012)
  • Malickova K, et al, Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases, Autoimmun Highlights (2012)
  • Gutierrez A, et al, Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn’s disease, Gut (2013)
  • Lukas M, et al, Anti-infliximab antibodies in routine clinical practice is it worth to assess them?, Czech Republic
  • Duricova D, et al, Predictors of sustained response to infliximab with Crohn’s disease: A single cohort study, Czech Republic
  • Chio C, et al, Etanercept Attenuates Traumatic Brain Injury in Rats by Reducing Brain TNF-α Contents and by Stimulating Newly Formed Neurogenesis, Mediators of Inflammation, (2013)
  • Bortlik M, et al,Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF- α theraphy during pregnancy: three-center study, Scandinavian Journal of Gastroenterology, (2013).
  • Jung Y, et al, Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis, (2013).
  • Bodini G., et al, Correlation Between Adalimumab Trough Serum Concentration, Anti-Adalimumab Antibodies and TNF-Alpha  Levels With Clinical Outcome in Patients Affected by Crohn’s Disease, (2013).
  • Grosen A., et al, Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease (2013).
  • Goldberg R., et al, Predictors of sub-therapeutic infliximab oradalimumab trough levels and anti-drug antibodies and their influence on therapeutic decisions,(2014).
  • Julsgaard M., et al, Intra-uterine Exposure to Anti-TNF-alpha therapy(ERA study):Infliximab and adalimumab cord blood levels correlate with maternal levels at birth, (2014).
  • Szepes Z., et al, Clinical utility of measuring serum TNF alpha level, anti TNF alpha levels and antibody titers in critical situations in inflammatory bowel disease and in psoriasis,(2014).
  • Krajcovicova A., et al, Delayed hypersensitivity reaction after initial dose of infliximab: a case report
  • Pallagi-Kunstár E., et al, Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.
  • Erdemli Ö., et al, In Vitro evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes.
  • Bortlik M, et al, Impact of Anti-Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children.

Product Citations